Abstract
Sebaceous carcinoma and sweat gland carcinoma (malignant tumors with apocrine and eccrine differentiation) are rare malignant skin adnexal tumors that differentiate toward sebaceous gland and eccrine and apocrine glands, respectively. Owing to the rarity of these carcinomas, standard treatments for advanced disease have not been established. Because the prognosis of patients with systemic metastasis is poor, a new treatment for these diseases is eagerly desired. Trophoblast cell surface antigen 2 (TROP2) and sacituzumab govitecan, an antibody–drug conjugate of TROP2, have attracted attention in the treatment of various solid tumors. In the current study, we immunohistochemically investigated TROP2 expression in 14 sebaceous carcinoma and 18 sweat gland carcinoma samples and found strong and relatively homogeneous TROP2 staining in both cancer types. The mean Histoscore, a semi-quantitative scoring ranging from 0 (negative) to 300, was 265.5 in sebaceous carcinoma and 260.0 in sweat gland carcinoma. These observations directly suggest that both sebaceous carcinoma and sweat gland carcinoma could be potentially treated with TROP2-targeted antibody–drug conjugates such as sacituzumab govitecan.
Highlights
Sebaceous carcinoma is a malignant tumor consisting of basaloid or squamous atypical cells with sebaceous differentiation
Sebaceous carcinoma has been classified into two types
Sebaceous carcinoma is composed of irregular lobules consisting of many undifferentiated cells and distinct sebaceous cells with foamy cytoplasm
Summary
Sebaceous carcinoma is a malignant tumor consisting of basaloid or squamous atypical cells with sebaceous differentiation. Sebaceous carcinoma has been classified into two types (ocular and extraocular) The former type occurs on the eyelids and originates from the Meibomian glands and glands of Zeis. Sebaceous carcinoma is composed of irregular lobules consisting of many undifferentiated cells and distinct sebaceous cells with foamy cytoplasm These cells are atypical, displaying nuclear and nucleolar pleomorphism [1]. We previously reported TROP2 expression in normal skin and skin appendages [11] and detected strong TROP2 expression in sebaceous and sweat glands. These findings prompted us to further investigate TROP2 expression in sebaceous carcinoma and sweat gland carcinoma. We analyzed TROP2 expression in both malignancies and examined whether TROP2 could be a therapeutic target for these malignant tumors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
